Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemorrhage and Infectious Complications in the Intensive Care Unit

被引:152
|
作者
MacLaren, Robert [1 ]
Reynolds, Paul M. [2 ]
Allen, Richard R. [3 ]
机构
[1] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO 80045 USA
[2] Univ Colorado Hosp, Dept Pharm, Aurora, CO USA
[3] Peak Stat Serv, Evergreen, CO USA
关键词
STRESS-ULCER PROPHYLAXIS; VENTILATOR-ASSOCIATED PNEUMONIA; COMMUNITY-ACQUIRED PNEUMONIA; SUPPRESSIVE MEDICATION USE; CRITICALLY III PATIENTS; BLEEDING PROPHYLAXIS; RISK-FACTORS; RANITIDINE; SUCRALFATE; PREVENTION;
D O I
10.1001/jamainternmed.2013.14673
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are commonly used to prevent gastrointestinal tract (GI) hemorrhage in critically ill patients. The stronger acid suppression of PPIs may reduce the rate of bleeding but enhance infectious complications, specifically pneumonia and Clostridium difficile infection (CDI). OBJECTIVE To evaluate the occurrence and risk factors for GI hemorrhage, pneumonia, and CDI in critically ill patients. DESIGN, SETTING, AND PARTICIPANTS A pharmacoepidemiological cohort study was conducted of adult patients requiring mechanical ventilation for 24 hours or more and administered either an H(2)RA or PPI for 48 hours or more while intubated across 71 hospitals between January 1, 2003, and December 31, 2008. Propensity score-adjusted and propensity-matched multivariate regression models were used to control for confounders. MAIN OUTCOMES AND MEASURES Primary outcomes were secondary diagnoses of International Classification of Diseases, Ninth Revision (ICD-9)-coded GI hemorrhage, pneumonia, and CDI occurring 48 hours or more after initiating invasive ventilation. RESULTS Of 35 312 patients, 13 439 (38.1%) received H2RAs and 21 873 (61.9%) received PPIs. Gastrointestinal hemorrhage (2.1% vs 5.9%; P <.001), pneumonia (27% vs 38.6%; P <.001), and CDI (2.2% vs 3.8%; P <.001) occurred less frequently in the H2RA group. After adjusting for propensity score and covariates, odds ratios of GI hemorrhage (2.24; 95% CI, 1.81-2.76), pneumonia (1.2; 95% CI, 1.03-1.41), and CDI (1.29; 95% CI, 1.04-1.64) were greater with PPIs. Similar results were obtained in the propensity-matched models of 8799 patients in each cohort. CONCLUSIONS AND RELEVANCE Proton pump inhibitors are associated with greater risks of GI hemorrhage, pneumonia, and CDI than H2RAs in mechanically ventilated patients. Numerous other risk factors are apparent. These data warrant confirmation in comparative prospective studies.
引用
收藏
页码:564 / 574
页数:11
相关论文
共 50 条
  • [21] Proton Pump Inhibitors Versus Histamine-2 Receptor Antagonists Likely Increase Mortality in Critical Care: An Updated Meta-Analysis
    Lee, Todd C.
    Wilson, Marnie Goodwin
    Lawandi, Alexander
    McDonald, Emily G.
    AMERICAN JOURNAL OF MEDICINE, 2021, 134 (03): : E184 - E188
  • [22] Histamine-2 receptor antagonists versus proton pump inhibitors for septic shock after lower gastrointestinal tract perforation: a retrospective cohort study using a national inpatient database
    Suzuki, Jun
    Sasabuchi, Yusuke
    Hatakeyama, Shuji
    Matsui, Hiroki
    Sasahara, Teppei
    Morisawa, Yuji
    Yamada, Toshiyuki
    Yasunaga, Hideo
    JOURNAL OF INTENSIVE CARE, 2020, 8 (01)
  • [23] PROTON PUMP INHIBITORS VERSUS HISTAMINE-2 RECEPTORS BLOCKERS IN PREVENTING GASTROINTESTINAL BLEEDING
    Aljawadi, Mohammad
    Badawi, Omar
    Onukwugha, Eberechukwu
    Tom, Sarah
    Magder, Laurence
    Zuckerman, Ilene
    CRITICAL CARE MEDICINE, 2014, 42 (12)
  • [24] The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: A meta-analysis
    Lin, Pei-Chin
    Chang, Chia-Hsuin
    Hsu, Ping-I
    Tseng, Pi-Lai
    Huang, Yaw-Bin
    CRITICAL CARE MEDICINE, 2010, 38 (04) : 1197 - 1205
  • [25] Histamine-2 receptor antagonists versus proton pump inhibitors for septic shock after lower gastrointestinal tract perforation: a retrospective cohort study using a national inpatient database
    Jun Suzuki
    Yusuke Sasabuchi
    Shuji Hatakeyama
    Hiroki Matsui
    Teppei Sasahara
    Yuji Morisawa
    Toshiyuki Yamada
    Hideo Yasunaga
    Journal of Intensive Care, 8
  • [26] Utilization and safety of proton-pump inhibitors and histamine-2 receptor antagonists in children and adolescents: an observational cohort study
    Ruigomez, A.
    Johansson, S.
    Nagy, P.
    Rodriguez, L. A. Garcia
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (12) : 2201 - 2209
  • [27] Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists
    Patel, Kajal S.
    Stephany, Brian R.
    Barnes, Julie F.
    Bauer, Seth R.
    Spinner, Michael L.
    PHARMACOTHERAPY, 2017, 37 (12): : 1507 - 1515
  • [28] Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients
    Qvigstad, G
    Arnestad, JS
    Brenna, E
    Waldum, HL
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1998, 33 (12) : 1244 - 1248
  • [29] Upper gastrointestinal bleeding in critically ill patients: proton-pump inhibitors, histamine-2 receptor antagonists or placebo? Many questions remain unanswered
    Garcia-Rayado, Guillermo
    Lanas, Angel
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (11) : 1881 - 1883
  • [30] Adherence to proton pump inhibitors and histamine-2 receptor antagonists used for the prevention of upper gastrointestinal events among non-specific NSAID users
    Sturkenboom, MCJM
    Burke, TA
    Tangelder, MJD
    Dieleman, JP
    Walton, S
    Goldstein, JL
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 347 - 348